NCT05184712 - Phase 3 Clinical Study of AK112 for NSCLC Patients | Biotech Hunter

Enrollment

322

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

June 28, 2024

Study Completion Date

November 2, 2025

Conditions

Non-Squamous Non-small Cell Lung Cancer

Interventions

DRUG

Ivonescimab (SMT112 or AK112) Injection

Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.

DRUG

Placebo Injection

Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou